Agilent has launched two new products designed to improve the speed and accuracy of clinical cancer research. Both products enable researchers to rapidly and accurately identify diseases-associated variants in tumor samples. This information can be vital to research in cancer treatments.
“Cancer is a complex disease caused by genetic alterations in multiple genes, many of which are present at very low frequency,” says Agilent’s Jacob Thaysen.
Non-inherited changes in the DNA of a multicellular organism, also known as “somatic variants,” can be extremely difficult to detect. The Agilent HaloPlexHS Target Enrichment System enables clinical researchers to identify low-frequency somatic variants in solid tumors and blood-related cancers. HaloPlexHS incorporates more than one million unique molecular barcodes for accurate detection of alleles (specific gene sequences) at low frequencies.
“I expect HaloPlexHS to be the new clinical research standard for accurate low-frequency variant identification,” says Dr. Eric Duncavage at Washington University in St. Louis, Missouri.
Oncogenes are genes that have the potential to cause cancer, while antioncogenes (tumor suppressor genes) help protect cells from cancer. Agilent ClearSeq Comprehensive Cancer Panels provide an accelerated solution for the analysis of many oncogenes and tumor suppressors. ClearSeq targets 151 key oncology genes containing disease-associated variants, and allows clinical researchers to rapidly profile multiple mutations present in cancer samples. The solution was developed in collaboration with researchers at Washington University.
“Agilent offers a unique set of solutions that provide a more comprehensive view of cancer,” Thaysen says, “from discovery research through diagnostics.”
For Research Use only. Not for use in Diagnostic Procedures.
For more information go to: